KOLMAR KOREA Transfers Pharmaceutical Division for 336.3 Billion KRW
[Asia Economy Reporter Hwang Yoon-joo] Kolmar Korea announced on the 27th that it has decided to transfer its pharmaceutical business division, excluding the toothpaste business, to IMM Rose Gold 4 Private Equity Partnership for 336.3 billion KRW in order to improve its financial structure and focus on core competencies through restructuring the group’s business structure.
In this regard, the Korea Exchange has decided to suspend trading of Kolmar Korea’s shares until 9 a.m. on the 28th.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- Given Grants, Then Says "No Launch" ... Innovative Korean Technology Ultimately Forced Overseas
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- Han Donghoon: "If Martial Law Had Not Been Stopped, People Power Party Would Not Exist... Unified Candidacy Depends on the Will of the People"
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
Additionally, Kolmar Korea stated that it will hold an extraordinary general meeting of shareholders at 10 a.m. on July 7 at the Kolmar BNH Leaders Room in Jeonui-myeon, Sejong City, to approve this matter.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Cheaper Than Candy, Yet Impossible to Find... Fears of a 'Pediatric Medical Crisis' as Pharmaceutical Companies Halt Production [Why&Next]](https://cwcontent.asiae.co.kr/asiaresize/307/2026051910065268365_1779152813.jpg)
